Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine/Islatravir (100 mg/0.25 mg) in HIV-1 infection
NCT05766501Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Mar 2023; status: active, not recruiting.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05766501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766501.